{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T05:40:16Z","timestamp":1775626816320,"version":"3.50.1"},"reference-count":131,"publisher":"Informa UK Limited","issue":"13-14","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-186134"],"award-info":[{"award-number":["PJT-186134"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Pharmacogenomics"],"published-print":{"date-parts":[[2025,9,22]]},"DOI":"10.1080\/14622416.2025.2580271","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T08:00:39Z","timestamp":1763625639000},"page":"529-542","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Cancer genetics and response to oncolytic virus treatment for ovarian cancer"],"prefix":"10.1080","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4427-2361","authenticated-orcid":false,"given":"Erin L.","family":"Fletcher","sequence":"first","affiliation":[{"name":"University of Ottawa","place":["Ottawa, Canada"]},{"name":"Ottawa Hospital Research Institute","place":["Ottawa, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4764-8771","authenticated-orcid":false,"given":"Alison O.","family":"Cudmore","sequence":"additional","affiliation":[{"name":"University of Ottawa","place":["Ottawa, Canada"]},{"name":"Ottawa Hospital Research Institute","place":["Ottawa, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7644-7189","authenticated-orcid":false,"given":"Barbara C.","family":"Vanderhyden","sequence":"additional","affiliation":[{"name":"University of Ottawa","place":["Ottawa, Canada"]},{"name":"Ottawa Hospital Research Institute","place":["Ottawa, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.10.030"},{"key":"e_1_3_5_4_1","unstructured":"Survival statistics for ovarian cancer [Internet]. Canadian Cancer Society. [cited 2025 Jul 8]. Available from: https:\/\/cancer.ca\/en\/cancer-information\/cancer-types\/ovarian\/prognosis-and-survival\/survival-statistics"},{"key":"e_1_3_5_5_1","unstructured":"Detection [Internet]. Ovarian Cancer Canada. [cited 2025 Jun 24]. Available from: https:\/\/ovariancanada.org\/detection"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaa015"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.21037\/gs-20-325"},{"key":"e_1_3_5_8_1","unstructured":"What is ovarian cancer? [Internet]. Canadian Cancer Society. [cited 2025 May 28]. Available from: https:\/\/cancer.ca\/en\/cancer-information\/cancer-types\/ovarian\/what-is-ovarian-cancer"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2016.0024"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20040952"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1643"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026252"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom13010159"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.08.005"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15461-z"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-023-01094-5"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0500"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-023-00970-w"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158412"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-022-02169-x"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104390"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10080244"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S105862"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13793"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.37349\/ei.2024.00177"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14080819"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00077"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.01.001"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.107"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/v3060920"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102316"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15235694"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-18-0504"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4663"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01407-6"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2024.110238"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-230083"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2020.06.010"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.2217\/fvl-2016-0129"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens14020140"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2023.0202"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells12101351"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.06.006"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2012.11.007"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2013.06.003"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.080078197"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1998.9123"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-0016(16)36512-1"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2011.0020"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.3390\/v8050134"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-9065-8_11"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.5.2357-2366.2004"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.3390\/v16060870"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1272351"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10061541"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005449"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1412896"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI9744"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-020-00646-3"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18022"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2011.01.006"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.707290"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02789331"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2017.04.001"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061504"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.3390\/cimb45060307"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)00131-4"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.19473"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.3390\/v10020090"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0439"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00241-1"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.3390\/v16121933"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.898631"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02705-05"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.aivir.2016.07.001"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002446"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.20114"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2004.08.015"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.276"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx367.047"},{"key":"e_1_3_5_81_1","unstructured":"McCart A. A single-arm open-label phase 2 study of JX-594 (thymidine kinase-deactivated vaccinia virus plus GM-CSF) administered by 5\u00a0weekly intravenous (IV) infusions in patients with peritoneal carcinomatosis of ovarian cancer origin [Internet]. clinicaltrials.gov; Report no.: NCT02017678. Available from 2014 [cited 2025 Jul 9]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02017678"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00756-10"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1457-z"},{"key":"e_1_3_5_84_1","unstructured":"Michael A Wilson W Sunshine S et al. A randomised phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC)."},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0244"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.1007"},{"key":"e_1_3_5_87_1","unstructured":"Holloway RW. Efficacy & safety of olvi-vec and platinum-doublet + bevacizumab compared to physician\u2019s choice of chemotherapy and bevacizumab in platinum-resistant\/refractory ovarian cancer (PRROC) (OnPrime GOG-3076) [Internet]. clinicaltrials.gov; Report no.: NCT05281471. Available from 2025 [cited 2025 Jul 9]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05281471"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.232439"},{"issue":"6","key":"e_1_3_5_89_1","first-page":"1523","article-title":"Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer1","volume":"5","author":"Coukos G","year":"1999","unstructured":"Coukos G, Makrigiannakis A, Kang EH, et al. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer1. Clin Cancer Res. 1999;5(6):1523\u20131537.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2010.53"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1006\/mthe.2000.0133"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2900"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.08.020"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-016-0282-3"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28631"},{"key":"e_1_3_5_96_1","unstructured":"Blazer D. A phase I trial of talimogene laherparepvec for the treatment of peritoneal surface malignancies [Internet]. clinicaltrials.gov; Report no.: NCT03663712. Available from 2024 [cited 2025 Jun 24]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03663712"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910522"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.7.3549-3558.2006"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.3390\/v7112905"},{"key":"e_1_3_5_100_1","unstructured":"The p53 tumor suppressor protein. [Internet]. National Center for Biotechnology Information (US); 1998 [cited 2025 Jun 6]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK22268\/"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1994.tb06957.x"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600006"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301402"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300363"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.06.003"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.161"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-15-0188-T"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002929"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1409076111"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00478-06"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph17121662"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.276.5320.1845"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-24-0906"},{"key":"e_1_3_5_114_1","doi-asserted-by":"crossref","unstructured":"Drymiotou S Queval CJ Tyson KE et al. Vinorelbine enhances the efficacy of GM-CSF-armed oncolytic vaccinia virus in a preclinical model of ovarian high grade serous carcinoma [Internet]. bioRxiv; 2025 [cited 2025 Jul 9]. p. 2025.02.04.636413. Available from: https:\/\/www.biorxiv.org\/content\/10.1101\/2025.02.04.636413v2","DOI":"10.1101\/2025.02.04.636413"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2016.34"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.04.014"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2709"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200826"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56482-w"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.3390\/diseases10030052"},{"key":"e_1_3_5_121_1","unstructured":"Block MS Villella J. Oncolytic adenovirus coding for TNFa and IL2 (TILT-123) with pembrolizumab or pembrolizumab (phase 1a and 2) and pegylated liposomal doxorubicin (phase 1b) as treatment for ovarian cancer. (prota) [Internet]. clinicaltrials.gov; Report no.: NCT05271318. Available from 2025 [cited 2025 Jul 9]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05271318"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14754"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao1613"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.3390\/v16060920"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002096"},{"key":"e_1_3_5_126_1","first-page":"120","article-title":"Adenoviral-delivered HE4-HSV-tk sensitizes ovarian cancer cells to ganciclovir","volume":"15","author":"Rawlinson JW","year":"2013","unstructured":"Rawlinson JW, Vaden K, Hunsaker J, et al. Adenoviral-delivered HE4-HSV-tk sensitizes ovarian cancer cells to ganciclovir. Gene Ther Mol Biol. 2013;15:120\u2013130.","journal-title":"Gene Ther Mol Biol"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)90013-1"},{"issue":"12","key":"e_1_3_5_128_1","first-page":"1571","article-title":"Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir","volume":"1","author":"Rosenfeld ME","year":"1995","unstructured":"Rosenfeld ME, Feng M, Michael SI, et al. Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir. Cancer Res. 1995;1(12):1571\u20131580.","journal-title":"Cancer Res"},{"key":"e_1_3_5_129_1","doi-asserted-by":"publisher","DOI":"10.1006\/mthe.2000.0194"},{"key":"e_1_3_5_130_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2852"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094050"},{"key":"e_1_3_5_132_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040983"},{"key":"e_1_3_5_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2020.10.009"}],"container-title":["Pharmacogenomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14622416.2025.2580271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T17:20:17Z","timestamp":1764523217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14622416.2025.2580271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":131,"journal-issue":{"issue":"13-14","published-print":{"date-parts":[[2025,9,22]]}},"alternative-id":["10.1080\/14622416.2025.2580271"],"URL":"https:\/\/doi.org\/10.1080\/14622416.2025.2580271","relation":{},"ISSN":["1462-2416","1744-8042"],"issn-type":[{"value":"1462-2416","type":"print"},{"value":"1744-8042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgs20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgs20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-07-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}